Clinical trial
Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome
NCT00190866 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190866 |
|---|---|
| Title | Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome |
| Official title | Dose Response Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Boehringer Ingelheim Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fibromyalgia |
| Intervention type | Drug |
| Interventions | Duloxetine, placebo |
| Enrollment | 210 |
| Start date | Jun 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 6, 2007 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: